Works matching DE "VACCINE trials"
Results: 1109
Investigational RSV Vaccine Yields Positive Preliminary Data in Head-to-Head Comparison with Arexvy.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
Phase 3 Trial of Combination Flu/SARS-CoV-2 Vaccine Meets All Primary Endpoints: Moderna.
- Published in:
- Patient Care (Online), 2024, p. 3
- By:
- Publication type:
- Article
FDA Approves First mRNA Vaccine Against RSV for Adults Aged ≥60 Years: Daily Dose.
- Published in:
- Patient Care (Online), 2024, p. 2
- Publication type:
- Article
Positive results spur race for Ebola vaccine.
- Published in:
- Nature, 2014, v. 516, n. 7529, p. 15, doi. 10.1038/516015a
- By:
- Publication type:
- Article
细胞源禽流感病毒三价灭活疫苗（H5N1 Re-11 株+ Re-12株、H7N9 H7-Re3株）免疫效力研究.
- Published in:
- Chinese Journal of Preventive Veterinary Medicine / Zhongguo Yufang Shouyi Xuebao, 2022, v. 44, n. 3, p. 295, doi. 10.3969/j.issn.1008-0589.202102006
- By:
- Publication type:
- Article
HUMANIZED MOUSE MODELS AND HUMAN VIRUSES.
- Published in:
- Lucrari Stiintifice: Seria Medicina Veterinara, 2020, v. 63, n. 3, p. 235
- By:
- Publication type:
- Article
RNA-Based COVID-19 vaccine candidates with clinical phase trials in progress.
- Published in:
- Turkish Journal of Medical Sciences, 2021, v. 51, p. 3246, doi. 10.3906/sag-2104-139
- By:
- Publication type:
- Article
Allergic reactions against Covıd-19 vaccines.
- Published in:
- Turkish Journal of Medical Sciences, 2021, v. 51, n. 5, p. 2233, doi. 10.3906/sag-2104-329
- By:
- Publication type:
- Article
Linking S. aureus Immune Evasion Mechanisms to Staphylococcal Vaccine Failures.
- Published in:
- Antibiotics (2079-6382), 2024, v. 13, n. 5, p. 410, doi. 10.3390/antibiotics13050410
- By:
- Publication type:
- Article
Cost-Effectiveness of Introducing Nuvaxovid to COVID-19 Vaccination in the United Kingdom: A Dynamic Transmission Model.
- Published in:
- Vaccines, 2025, v. 13, n. 2, p. 187, doi. 10.3390/vaccines13020187
- By:
- Publication type:
- Article
Plasma microRNAs to Select Optimal Patients for Antibody Production from Anti-Addiction Vaccines.
- Published in:
- Vaccines, 2025, v. 13, n. 2, p. 181, doi. 10.3390/vaccines13020181
- By:
- Publication type:
- Article
Prevalence of Adverse Events Reported Following the First Dose of COVID-19 Vaccines in Bahia State, Brazil, from 2021 to 2022.
- Published in:
- Vaccines, 2025, v. 13, n. 2, p. 161, doi. 10.3390/vaccines13020161
- By:
- Publication type:
- Article
A Pentavalent HIV-1 Subtype C Vaccine Containing Computationally Selected gp120 Strains Improves the Breadth of V1V2 Region Responses.
- Published in:
- Vaccines, 2025, v. 13, n. 2, p. 133, doi. 10.3390/vaccines13020133
- By:
- Publication type:
- Article
Cost-Effectiveness of Introducing Nuvaxovid to COVID-19 Vaccination in the United Kingdom: A Dynamic Transmission Model.
- Published in:
- Vaccines, 2025, v. 13, n. 2, p. 187, doi. 10.3390/vaccines13020187
- By:
- Publication type:
- Article
Plasma microRNAs to Select Optimal Patients for Antibody Production from Anti-Addiction Vaccines.
- Published in:
- Vaccines, 2025, v. 13, n. 2, p. 181, doi. 10.3390/vaccines13020181
- By:
- Publication type:
- Article
Prevalence of Adverse Events Reported Following the First Dose of COVID-19 Vaccines in Bahia State, Brazil, from 2021 to 2022.
- Published in:
- Vaccines, 2025, v. 13, n. 2, p. 161, doi. 10.3390/vaccines13020161
- By:
- Publication type:
- Article
A Pentavalent HIV-1 Subtype C Vaccine Containing Computationally Selected gp120 Strains Improves the Breadth of V1V2 Region Responses.
- Published in:
- Vaccines, 2025, v. 13, n. 2, p. 133, doi. 10.3390/vaccines13020133
- By:
- Publication type:
- Article
Safety, Tolerability, and Immunogenicity of the Invaplex AR-Detox Shigella Vaccine Co-Administered with the dmLT Adjuvant in Dutch and Zambian Adults: Study Protocol for a Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase Ia/b Clinical Trial
- Published in:
- Vaccines, 2025, v. 13, n. 1, p. 48, doi. 10.3390/vaccines13010048
- By:
- Publication type:
- Article
Reactogenicity and Immunogenicity Against MPXV of the Intradermal Administration of Modified Vaccinia Ankara Compared to the Standard Subcutaneous Route.
- Published in:
- Vaccines, 2025, v. 13, n. 1, p. 32, doi. 10.3390/vaccines13010032
- By:
- Publication type:
- Article
Multi-Antigen Elephant Endotheliotropic Herpesvirus (EEHV) mRNA Vaccine Induces Humoral and Cell-Mediated Responses in Mice.
- Published in:
- Vaccines, 2024, v. 12, n. 12, p. 1429, doi. 10.3390/vaccines12121429
- By:
- Publication type:
- Article
Antibody Avidity Maturation Following Booster Vaccination with an Intranasal Adenovirus Salnavac Vaccine.
- Published in:
- Vaccines, 2024, v. 12, n. 12, p. 1362, doi. 10.3390/vaccines12121362
- By:
- Publication type:
- Article
Cell-Free Screening, Production and Animal Testing of a STI-Related Chlamydial Major Outer Membrane Protein Supported in Nanolipoproteins.
- Published in:
- Vaccines, 2024, v. 12, n. 11, p. 1246, doi. 10.3390/vaccines12111246
- By:
- Publication type:
- Article
Field Trial with Vaccine Candidates Against Bovine Tuberculosis Among Likely Infected Cattle in a Natural Transmission Setting.
- Published in:
- Vaccines, 2024, v. 12, n. 10, p. 1173, doi. 10.3390/vaccines12101173
- By:
- Publication type:
- Article
Reproducibility Assessment of Enzyme-Linked Immunosorbent Assays to Detect Anti-HPV16 L1-Specific IgG1, IgG3, IgA, and IgM Antibodies.
- Published in:
- Vaccines, 2024, v. 12, n. 10, p. 1108, doi. 10.3390/vaccines12101108
- By:
- Publication type:
- Article
Navigating the Landscape of B Cell Mediated Immunity and Antibody Monitoring in SARS-CoV-2 Vaccine Efficacy: Tools, Strategies and Clinical Trial Insights.
- Published in:
- Vaccines, 2024, v. 12, n. 10, p. 1089, doi. 10.3390/vaccines12101089
- By:
- Publication type:
- Article
Evaluating Nanoparticulate Vaccine Formulations for Effective Antigen Presentation and T-Cell Proliferation Using an In Vitro Overlay Assay.
- Published in:
- Vaccines, 2024, v. 12, n. 9, p. 1049, doi. 10.3390/vaccines12091049
- By:
- Publication type:
- Article
Advancing Human Vaccine Development Using Humanized Mouse Models.
- Published in:
- Vaccines, 2024, v. 12, n. 9, p. 1012, doi. 10.3390/vaccines12091012
- By:
- Publication type:
- Article
Long-Term Immunogenicity Study of an Aluminum Phosphate-Adjuvanted Inactivated Enterovirus A71 Vaccine in Children: An Extension to a Phase 2 Study.
- Published in:
- Vaccines, 2024, v. 12, n. 9, p. 985, doi. 10.3390/vaccines12090985
- By:
- Publication type:
- Article
Maternal Vaccination for the Prevention of Infantile RSV Disease: An Overview of the Authorized, In-Progress, and Rejected Vaccine Candidates.
- Published in:
- Vaccines, 2024, v. 12, n. 9, p. 980, doi. 10.3390/vaccines12090980
- By:
- Publication type:
- Article
PREVAX: A Phase I Clinical Trial of an EGF-Based Vaccine in Moderate-to-Severe COPD Patients.
- Published in:
- Vaccines, 2024, v. 12, n. 8, p. 833, doi. 10.3390/vaccines12080833
- By:
- Publication type:
- Article
Field Trials of Live and Inactivated Camelpox Vaccines in Kazakhstan.
- Published in:
- Vaccines, 2024, v. 12, n. 6, p. 685, doi. 10.3390/vaccines12060685
- By:
- Publication type:
- Article
Feasibility of Using a Type I IFN-Based Non-Animal Approach to Predict Vaccine Efficacy and Safety Profiles.
- Published in:
- Vaccines, 2024, v. 12, n. 6, p. 583, doi. 10.3390/vaccines12060583
- By:
- Publication type:
- Article
SARS-CoV-2 Neutralization Assays Used in Clinical Trials: A Narrative Review.
- Published in:
- Vaccines, 2024, v. 12, n. 5, p. 554, doi. 10.3390/vaccines12050554
- By:
- Publication type:
- Article
Current Progress in Vaccines against Merkel Cell Carcinoma: A Narrative Review and Update.
- Published in:
- Vaccines, 2024, v. 12, n. 5, p. 533, doi. 10.3390/vaccines12050533
- By:
- Publication type:
- Article
The Limitations of a Hypothetical All-Variant COVID-19 Vaccine: A Simulation Study.
- Published in:
- Vaccines, 2024, v. 12, n. 5, p. 532, doi. 10.3390/vaccines12050532
- By:
- Publication type:
- Article
A TriAdj-Adjuvanted Chlamydia trachomatis CPAF Protein Vaccine Is Highly Immunogenic in Pigs.
- Published in:
- Vaccines, 2024, v. 12, n. 4, p. 423, doi. 10.3390/vaccines12040423
- By:
- Publication type:
- Article
Global Disparities in Access to Vaccine Clinical Trials: A Review of the Literature.
- Published in:
- Vaccines, 2024, v. 12, n. 4, p. 348, doi. 10.3390/vaccines12040348
- By:
- Publication type:
- Article
Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine.
- Published in:
- Vaccines, 2024, v. 12, n. 3, p. 325, doi. 10.3390/vaccines12030325
- By:
- Publication type:
- Article
The Chimeric Chaoyang-Zika Vaccine Candidate Is Safe and Protective in Mice.
- Published in:
- Vaccines, 2024, v. 12, n. 2, p. 215, doi. 10.3390/vaccines12020215
- By:
- Publication type:
- Article
Persistence of Anti-SE36 Antibodies Induced by the Malaria Vaccine Candidate BK-SE36/CpG in 5–10-Year-Old Burkinabe Children Naturally Exposed to Malaria.
- Published in:
- Vaccines, 2024, v. 12, n. 2, p. 166, doi. 10.3390/vaccines12020166
- By:
- Publication type:
- Article
Mapping the Cognitive Biases Related to Vaccination: A Scoping Review of the Literature.
- Published in:
- Vaccines, 2023, v. 11, n. 12, p. 1837, doi. 10.3390/vaccines11121837
- By:
- Publication type:
- Article
The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium.
- Published in:
- Vaccines, 2023, v. 11, n. 12, p. 1784, doi. 10.3390/vaccines11121784
- By:
- Publication type:
- Article
Pre-Clinical Safety and Immunogenicity Study of a Coronavirus Protein-Based Subunit Vaccine for COVID-19.
- Published in:
- Vaccines, 2023, v. 11, n. 12, p. 1771, doi. 10.3390/vaccines11121771
- By:
- Publication type:
- Article
Development of A Standardized Opsonophagocytosis Killing Assay for Group B Streptococcus and Assessment in an Interlaboratory Study.
- Published in:
- Vaccines, 2023, v. 11, n. 11, p. 1703, doi. 10.3390/vaccines11111703
- By:
- Publication type:
- Article
A Field Efficacy Trial of Recombinant Porcine Circovirus Type 2d Vaccine in Three Herds.
- Published in:
- Vaccines, 2023, v. 11, n. 9, p. 1497, doi. 10.3390/vaccines11091497
- By:
- Publication type:
- Article
Replicate Testing of Clinical Endpoints Can Prevent No-Go Decisions for Beneficial Vaccines.
- Published in:
- Vaccines, 2023, v. 11, n. 9, p. 1501, doi. 10.3390/vaccines11091501
- By:
- Publication type:
- Article
CD4 + T Cell Responses to Toxoplasma gondii Are a Double-Edged Sword.
- Published in:
- Vaccines, 2023, v. 11, n. 9, p. 1485, doi. 10.3390/vaccines11091485
- By:
- Publication type:
- Article
Sending a Message: Use of mRNA Vaccines to Target the Tumor Immune Microenvironment.
- Published in:
- Vaccines, 2023, v. 11, n. 9, p. 1465, doi. 10.3390/vaccines11091465
- By:
- Publication type:
- Article
Maternal and Infant Histo-Blood Group Antigen (HBGA) Profiles and Their Influence on Oral Rotavirus Vaccine (Rotarix TM) Immunogenicity among Infants in Zambia.
- Published in:
- Vaccines, 2023, v. 11, n. 8, p. 1303, doi. 10.3390/vaccines11081303
- By:
- Publication type:
- Article
Comparison of Humoral Antibody Responses and Seroconversion Rates between Two Homologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination in Patients Undergoing Maintenance Hemodialysis.
- Published in:
- Vaccines, 2023, v. 11, n. 7, p. 1161, doi. 10.3390/vaccines11071161
- By:
- Publication type:
- Article